QIAGEN N.V. (QGEN) is poised to grow in the upcoming quarters, backed by its robust progress in expanding the test menu options. The company’s expansive Molecular Diagnostics portfolio continues to be bolstered by several innovations. In addition, sound financial stability instills optimism.Meanwhile, QIAGEN’s operations are vulnerable to macroeconomic volatilities, which can adversely affect its financial results. Any adverse developments in the company’s commercial partnerships may impact its sales and co ...